Drug intelligence / Profile preview

DGD

Development stage: Unknown
Lead developer: MediWound
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Topical

Overview

DGD is a topical pharmaceutical drug developed by MediWound Ltd. It is a combination product consisting of lyophilized enzymes, specifically purified Bromelain from pineapple stem (referred to as Debrase powder), dissolved in a Gel Vehicle. DGD is designed for enzymatic debridement, a process that removes dead and traumatized tissue, known as eschar, from partial thickness thermal burn wounds. This action aims to prevent local and systemic infections, reduce inflammation, and minimize the extension of the original damage.

Targets

Non-viable eschar proteins

Beyond the preview

Go deeper on DGD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DGD.

Explore the full profile